Jin-Soo Kim, Ph.D., was one of the first to report, in January 2013, on targeted genome modifications in human cells using CRISPR-Cas9. An international leader in CRISPR technology, he has been recognized for his work making the CRISPR-Cas9 gene editing system more precise and stable. Kim, professor and director at the Center for Genome Engineering, Seoul National University, will speak at OHSU.
“Genome-wide target specificity of CRISPR base editors”
Knight Cancer Research Bldg., room 1015
Tuesday, April 9, noon to 1 p.m.
Kim has applied CRISPR technology to human stem cells and embryos, animals and plants, offering great potential for broad applications in medicine and biotechnology. These tools are now used for genome editing in thousands of labs all around the world.
A collaborator of Shoukhrat Mitalipov, Ph.D., and Paula Amato, M.D., he co-authored the groundbreaking discovery reported in Nature — the successful removal of a lethal genetic defect in human embryos. The discovery and widespread development of methods to edit the human genome is a truly revolutionary advance in biology. He has published more than 150 articles and filed 50 patent applications, mostly in the field of gene regulation and genome editing
Image above from Nature paper reporting the successful removal, using CRISPR technology, of a lethal genetic defect in human embryos.
Kim was a member of the organizing committee for the Second International Genome Editing Summit in Hong Kong. The summit continued to advance the global dialogue on the science, application, ethics, and governance of human genome editing.
Light refreshments will be provided.
Sponsored by the Center for Embryonic Cell and Gene Therapy and the Office of the Senior Vice President for Research.
For more information, email Amy Koski at email@example.com.